

Schizophrenia Management Approaches: A Look at Progress and Challenges

Kesha Pareshkumar Patel, Terry L. Oroszi

Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Fairborn, OH, USA
Email: terry.oroszi@wright.edu

How to cite this paper: Patel, K.P. and Oroszi, T.L. (2025) Schizophrenia Management Approaches: A Look at Progress and Challenges. *World Journal of Neuroscience*, 15, 13-34.
<https://doi.org/10.4236/wjns.2025.151003>

Received: October 7, 2024

Accepted: January 18, 2025

Published: January 21, 2025

Copyright © 2025 by author(s) and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Schizophrenia is a severely impacting serious mental illness that presents numerous difficulties to those who suffer from it, their families, and society. While much effort has been invested in understanding successful treatments, it is still a major issue in public health. This review assesses the advances and issues in the management of schizophrenia in the 21st century, paying special attention to drugs, psychosocial techniques, and connected specialty care. Medications for antipsychotics and psychosocial procedures have shown potential to relieve symptoms and improve functioning, while Recovery-Oriented Care and Psychological Trauma Recovery focus on early diagnosis, combined treatment, and sustained attention. However, many questions remain that need to be answered, including access to care, unmet needs, and discrepancies. Today's neuroscience research, along with genetic studies and novel therapy options, such as long-acting injectable antipsychotics or telepsychiatry, offers the possibility of further progress being made. Future research exploring fields such as neuroscience, genetics, and implementation science could lead to increasingly effective strategies for people with schizophrenia.

Keywords

Schizophrenia, Antipsychotics, Psychosocial Interventions, Coordinated Specialty Care, Evidence-Based Models

1. Introduction

Schizophrenia is a serious and complex mental illness with profound consequences for affected individuals, their families, and society. It affects people's ability to think, feel and behave [1]. There is a greater probability of poverty, unemployment, homelessness, poorer physical health, and premature death for those with the condition [2]. Furthermore, stigma and prejudice are commonplace for those with

schizophrenia, which can have a negative impact on their quality of life and their ability to receive adequate treatment [3].

Affecting about 1% of the population worldwide, schizophrenia can occur at any age, although it most commonly manifests between the ages of 15 and 30. The etiology of schizophrenia is multifaceted, involving a combination of genetic, environmental, and neurobiological factors. Genetic predisposition plays a significant role, with people with a family history of schizophrenia being at increased risk. Environmental factors, such as prenatal exposure to infections, malnutrition, and psychosocial stressors, also contribute to the development of the disorder. Neurobiologically, abnormalities in brain structure and function, particularly in neurotransmitter systems such as dopamine, are implicated in schizophrenia [4].

The condition often presents with acute episodes, and very few individuals return to normal life after multiple episodes. Approximately two-thirds of those affected experience regular episodes that alternate with periods of remission or chronic worsening, which can prevent them from living independently. Therefore, early identification followed by intervention is essential for a better outcome [4]. Researchers and professionals are working hard to handle the life-altering effects of schizophrenia effectively. Medications such as antipsychotics and therapy can be reliable forms of treatment, but tailoring an individualized approach for each patient may be complex [5].

Fortunately, recent advances in psychiatry have brought renewed optimism about achieving better outcomes for those living with this disorder. Numerous notable developments have occurred in the last few years, allowing people with this disorder to live healthier and more fulfilling lives. Innovative treatments such as long-acting injectable antipsychotics [6] and telepsychiatry [7], together with evidence-based care models [8], offer new possibilities for managing schizophrenia symptoms. However, due to ongoing inequalities in healthcare services, these lifesaving treatments remain inaccessible to many people. The National Alliance on Mental Illness has highlighted this need for improved accessibility when it comes to providing quality mental health assistance.

This review seeks to explore the current practices involved in managing schizophrenia, from medications and psychosocial interventions to coordinated specialty care. Furthermore, it will also cover novel treatments and technologies as a means of improving the delivery of healthcare for this disorder. Additionally, it seeks to identify how stigma impacts health outcomes for people with schizophrenia and focuses on person-centered approaches that can improve access to healthcare regardless of socioeconomic or other disparities.

2. Medications

2.1. Antipsychotic Medications

Antipsychotic medications remain the cornerstone of the treatment of schizophrenia, as they have been proven to reduce symptoms associated with psychosis. These medications are also used to treat other psychotic disorders, such as schizoaffective

disorder and bipolar disorder [9]. By targeting neurotransmitters such as dopamine and serotonin in the brain, these drugs are believed to influence positive symptomology (hallucinations/delusions) and negative symptomology (apathy/social withdrawal). This powerful therapeutic option continues to offer hope to those with this chronic illness. Antipsychotic medications are invaluable for the treatment of schizophrenia, with two distinct classes at the forefront. First-generation (typical) antipsychotics are associated with a higher risk of extrapyramidal side effects such as parkinsonism and dystonia, although they have been proven effective in reducing symptoms since their development in the 1950s [10]. Second-generation drugs can offer fewer movement disorders but may present more metabolic problems, such as weight gain or hyperlipidemia [10]. First-generation antipsychotics include drugs such as chlorpromazine (Thorazine), haloperidol (Haldol), and perphenazine (Trilafon). Second-generation antipsychotics include newer drugs such as aripiprazole (Abilify), risperidone (Risperdal), quetiapine (Seroquel), and olanzapine (Zyprexa).

2.2. Mechanism of Action

Antipsychotics work by inhibiting dopamine receptors in the brain, and this can reduce the symptoms of schizophrenia that are caused by an excess of dopaminergic activity in the mesolimbic and mesocortical pathways [9]. Unfortunately, these medications have side effects, such as motor disturbances and cognitive impairments, which arise from impeding dopamine receptors in other parts of the brain, including the nigrostriatal and tuberoinfundibular pathways [11]. Furthermore, although antipsychotics primarily affect dopamine and serotonin receptors, they can also modify levels of neurotransmitters, including glutamate and GABA, since they can be involved in the production of schizophrenia [9].

Clozapine has been shown to be different from other antipsychotic medications and can be considered a third class on its own. The blockade rate of the D2 receptor in the striatum must reach below 65% for clozapine to take effect, suggesting that beyond D2 receptor activity, there are likely other pathways in its therapeutic effectiveness. Its effectiveness in treating treatment-resistant schizophrenia is unparalleled, though the exact reason why it works better than others is still unknown [9].

2.3. Side Effects

There are different side effects associated with each class of antipsychotic drug. First-generation antipsychotics (FGAs) tend to cause more side effects than second-generation antipsychotics (SGAs), but they may be more effective in treating specific symptoms. The most common side effects of FGA and SGAs include drowsiness, weight gain, dry mouth, and blurred vision [12]. According to a Leucht meta-analysis study, the tolerability of amisulpride was the best, with fewer discontinuations due to side effects than placebo. Haloperidol had the highest discontinuation rate compared with placebo. The drug most likely to cause extrapyramidal

side effects (EPSEs) was haloperidol, while weight gain and metabolic dysfunction were most commonly associated with the use of olanzapine and clozapine. Similar side effects were also observed in risperidone and quetiapine, but to a lesser extent [13].

There is a higher prevalence of modifiable cardiovascular risk factors in schizophrenia, and 33% of patients meeting the criteria for metabolic syndrome [14]. SGAs have higher rates of metabolic dysfunction, although FGAs like chlorpromazine also increase cardiometabolic risk. Cardiometabolic risks associated with FGAs have not been studied as extensively as those with SGAs. Clozapine and olanzapine both have the highest affinity for the 5-HT_{2C} and histamine (H₁) receptor affinity and the greatest potential for weight gain, which can occur early in the course of treatment [15].

2.3.1. Strategies to Manage Side Effects

Managing the side effects of antipsychotic medications, particularly SGAs, is crucial to improving patient outcomes and treatment adherence. Here are some strategies:

1) **Regular monitoring:** Regular monitoring of weight, blood glucose levels, and lipid profiles can help detect early signs of metabolic syndrome. This allows for timely interventions, such as dietary changes, increased physical activity, or medication adjustments.

2) **Lifestyle interventions:** Encouraging patients to adopt a healthy lifestyle, including a balanced diet and regular exercise, can mitigate weight gain and reduce the risk of metabolic syndrome. Behavioral interventions and support groups can also be beneficial.

3) **Medication adjustments:** If significant side effects occur, adjustment of dosage or switching to a different antipsychotic with a lower side effect profile may be necessary. For example, switching from olanzapine to aripiprazole, which has a lower risk of weight gain, might be considered.

4) **Pharmacological interventions:** In some cases, additional medications can be prescribed to manage side effects. For example, metformin can address weight gain and insulin resistance, while beta-blockers or anticholinergic agents can help manage EPSE.

5) **Patient education:** Educating patients about the potential side effects of their medications and involving them in decision-making can improve adherence and empower them to manage their health proactively.

2.3.2. Clozapine Monitoring Protocols

Clozapine is highly effective for treatment-resistant schizophrenia, but it carries significant risks, including agranulocytosis and myocarditis. Therefore, strict monitoring protocols are essential:

1) **Regular blood tests:** Patients taking clozapine must undergo regular blood tests to monitor white blood cell (WBC) counts and absolute neutrophil counts (ANCs). Initially, these tests are conducted weekly for the first six months, biweekly for the

next six months, and then monthly if stable.

2) Cardiovascular monitoring: Monitoring for signs of myocarditis and cardiomyopathy is crucial. This includes regular evaluations of heart rate, blood pressure, and symptoms such as chest pain or shortness of breath. Baseline and periodic electrocardiograms (ECGs) can also be recommended.

3) Patient and caregiver education: Educating patients and their caregivers about the signs and symptoms of agranulocytosis (e.g. fever, sore throat) and myocarditis (e.g. chest pain, fatigue) is essential for early detection and intervention. By implementing these strategies, healthcare providers can better manage the side effects of antipsychotic medications, particularly SGA, and improve the overall quality of life for individuals with schizophrenia.

2.4. Treatment-Resistant Schizophrenia

30% of patients with schizophrenia are estimated to not respond to medications. A person who does not respond to FGAs or SGAs at therapeutic doses and for a duration that is generally 6 - 8 weeks of antipsychotic therapy meets the criteria for schizophrenia, which is resistance to treatment [9]. Multiple studies and meta-analyses have shown that clozapine is superior to all other antipsychotics in TRS, though a network meta-analysis has challenged these results [16]. Approximately 40% - 70% of the patients having TRS do not respond to clozapine. For these patients, combining clozapine with other medications or non-pharmacological treatment options has proven to be an effective treatment plan, and the addition of other antipsychotic agents has been the most common strategy [17]. Some researchers hypothesized that the high-potency D2 blockade would enhance the weak D2 antagonistic properties. Therefore, the addition of risperidone to clozapine is beneficial [18]. However, another meta-analysis study did not show the benefits of clozapine-risperidone increase [17]. In addition, the addition of another antipsychotic agent also increases the risk of side effects [17].

Focusing on neurotransmitter systems may not be the most beneficial way to address TRS. Most medications aimed at treating schizophrenia and augmenting clozapine are dependent on neuroreceptor systems like DA, serotonin, and Glu. Therefore, uncovering which subsequent genes and pathways are the main contributors could create more effective therapeutic objectives [19]. There may be special pathways that can provide treatment for TRS compared to non-TRS, which underscores the importance of assessing whether TRS is a separate subclass of schizophrenia and how it can be best classified [19].

2.5. Role of Long-Acting Injectable Antipsychotics

With LAI antipsychotics, people with schizophrenia can now benefit from an innovative treatment option that helps reduce symptoms, improve adherence to medication regimens, and decrease the risk of hospitalization [20]. Long-acting injectable medications are administered as a shot every few weeks, allowing more flexibility and control over extended periods for those who face challenges in adhering

to oral therapies. These agents offer several potential advantages over traditional oral antipsychotics, including improved compliance, reduced risk of relapse, and lower EPS and TD rates [9].

Various long-acting injectable antipsychotics are available for the treatment of schizophrenia. Some examples include risperidone, olanzapine, paliperidone, and aripiprazole in SGA and haloperidol, flupentixol, zuclopenthixol, and fluphenazine in FGA [9]. Each of these antipsychotics has its own unique set of benefits and drawbacks. Risperidone is an effective antipsychotic with a relatively low risk of side effects. It is also one of the few antipsychotics that is FDA-approved for use in children and adolescents. Olanzapine is another effective antipsychotic with a low risk of side effects. However, it is associated with weight gain and metabolic problems, so close monitoring is necessary [21]. A study comparing the effectiveness of LAI and oral antipsychotics in preventing readmission in schizophrenic patients showed that LAIs reduced readmission rates by 29%. Furthermore, LAIs reduce readmission rates by 58% in patients with repeated admissions, showing more effectiveness in preventing hospitalization than oral antipsychotics when there are more readmissions [22]. Although LAIs have several advantages, many clinicians have not used them due to concerns about side effects, lack of knowledge, and high costs [22].

The use of long-acting injectable antipsychotics for the treatment of schizophrenia has both advantages and disadvantages. One advantage is that these medications can provide a more continuous and stable level of medication in the body, which can help prevent relapses and are easier to comply with than daily oral medication. A disadvantage is that they require frequent injections, which can be painful and uncomfortable and also carry a risk of injection site reactions [23].

Advantages of LAI over oral antipsychotics

- Daily administration is not required.
- Administration and transparency of adherence are guaranteed.
- Bioavailability is more consistent.
- The correlation between dosage and plasma levels is more predictable.
- It circumvents first-pass metabolism and has minimal gastrointestinal absorption problems.
- If patients do not take their medication, healthcare professionals can be alerted and intervene.
- Reduced likelihood of rebound symptoms and rapid relapses.
- The risk of unintentional or deliberate overdose is reduced.
- Contact between the patient and mental health team is conducted on a regular basis.

Disadvantages of LAI over oral antipsychotics

- The rate of dose titration is slow.
- Steady-state levels take longer to reach.
- Dose adjustment is less flexible.
- A delay in the disappearance of distressing and/or severe side effects.

- Leakage into the subcutaneous tissue and/or skin can cause irritation and lesions (especially with long-acting oily injectables).
- Frequently travel to outpatient clinics or home visits by community nurses for their administration.
- In some latitudes, it may be difficult to refrigerate long-acting injectable risperidone.
- Stigma perception.

2.6. Adherence to Medication and Its Importance

Medication adherence is a critical measure for the successful treatment of schizophrenia. Patients may suffer worsening symptoms and higher hospitalization rates [24]. Strategies to improve medication adherence include educating patients about their illness and providing support from family members [25]. Furthermore, involving patients in decision-making processes regarding their treatments can help address barriers that prevent individuals from adhering to medications [24].

The condition can be successfully treated with various medications tailored to specific symptoms. For example, anticholinergics help address extrapyramidal side effects, antidepressants address negative symptoms, and mood stabilizers target co-occurring affective issues [26]. To achieve optimal results in managing schizophrenia, creating a personalized treatment plan customized specifically for each patient is essential. Long-acting injectables and various antipsychotic medications offer healthcare professionals more options to devise the best course of action for their patients.

Table 1. Barriers to medication adherence.

Barrier	Description
Side Effects	Unpleasant side effects can discourage patients from continuing their medication. Addressing these side effects proactively is crucial.
Forgetfulness	Patients may forget to take their medication, especially if they have cognitive impairments.
Lack of Insight	Some patients may not think they need medication, a common problem in schizophrenia known as anosognosia.
Complex Regimens	Complicated medication schedules can be difficult to follow.
Stigma	Fear of stigmatization can prevent patients from taking their medications regularly.
Financial Constraints	The cost of medication can be a significant barrier for some patients.

Working with people suffering from schizophrenia is critical, as medication adherence plays an integral role over time in successful management [9]. By implementing the strategies and using innovative technologies listed below, patients can improve medication adherence, leading to better clinical outcomes and a better quality of life for patients with schizophrenia. **Table 1** outlines six barriers to medication adherence for individuals with schizophrenia.

Strategies to improve medication adherence

1) **Patient education:** Educating patients about their illness, the importance of medication adherence, and potential side effects can empower them to take an active role in their treatment. Understanding the benefits and risks associated with their medications can increase their willingness to adhere to the prescribed regimen.

2) **Family support:** Involving family members in the treatment process can provide additional support and encouragement for patients. Family members can help monitor medication adherence, recognize early signs of relapse, and provide emotional support.

3) **Shared decision-making:** Including patients in the decision-making process about their treatment plans can enhance their sense of control and commitment to treatment. Discussing treatment options, potential side effects, and patient preferences can lead to more personalized and acceptable treatment plans.

4) **Use of long-acting injectables (LAIs):** LAIs can be an effective option for patients with difficulty adhering to daily oral medications. These injectables provide a consistent level of medication in the body, reducing the risk of relapse due to missed doses.

5) **Regular follow-up:** Regular follow-up appointments with healthcare providers can help monitor medication adherence, address concerns or side effects, and make necessary adjustments to the treatment plan. Continuous engagement with healthcare providers can reinforce the importance of adherence.

6) **Addressing barriers:** Identifying and addressing barriers to medication adherence, such as forgetfulness, side effects, or lack of understanding, can improve adherence rates. Solutions may include using medication reminders, proactively managing side effects, and providing clear and simple instructions.

Innovative solutions and technologies

1) **Digital pills:** Digital pills are equipped with ingestible sensors that send a signal to a wearable patch when the medication is taken. This information is then transmitted to a mobile app, allowing patients and healthcare providers to monitor adherence in real-time.

2) **Mobile app reminders:** Mobile apps can provide reminders to take medication, track doses, and offer educational resources. These apps can also facilitate communication between patients and healthcare providers, making it easier to address any problems.

3) **Telepsychiatry:** Telepsychiatry can provide remote consultations and follow-ups, making it easier for patients to access care and remain engaged with their

treatment plans.

4) **Smart pill bottles:** Smart pill bottles can track when the bottle is opened and send reminders to patients if a dose is missed. These devices can also provide adherence data to healthcare providers.

5) **Wearable devices:** Wearable devices can monitor physiological indicators and provide reminders for medication. They can also track physical activity and sleep patterns, offering a more comprehensive view of the patient's health.

3. Psychosocial Intervention

Medication may be the most widely used treatment for schizophrenia, but psychosocial interventions can have an equally beneficial impact. These interventions, which address specific symptoms and promote better functioning, are crucial in helping to manage this complex disorder more effectively [27]. Psychosocial interventions improve the effect of pharmacological treatments by improving particular areas of personal functioning, improving clinical outcomes, and reducing relapses and hospitalizations [28].

3.1. Individual Therapy

Individual therapy is a widely studied psychosocial intervention for schizophrenia and can include a variety of therapies to address positive symptoms such as hallucinations or delusions, negative symptoms such as social withdrawal or apathy, emotional impairments, insight, and self-esteem. It includes various types of therapies, such as cognitive behavioral therapy (CBT), psychodynamic therapy, and other forms of talk therapy. For example, CBT is effective in many people with positive and negative behavioral symptoms [29]. Individual therapy allows for a personalized treatment approach. By addressing the patient's symptoms, personal history, and personal goals, the therapist can customize therapy sessions according to their specific needs. Patient participation can be improved with this individualized approach, which can increase patient motivation to make positive changes in the future [5].

3.2. Family Therapy

Family therapy empowers people with schizophrenia and their families by providing a platform to discuss communication issues, coping strategies, and problem-solving. By addressing the impact on family dynamics, this beneficial intervention method can reduce stress for caregivers while simultaneously improving interpersonal relationships within the home environment, ultimately reducing relapse rates [30]. According to various studies, family therapy is an effective intervention for the treatment of schizophrenia and can help people with the condition lead normal, productive lives and cope with their condition, reducing relapses and hospitalization rates [31]. Family therapy has also been shown to improve adherence to treatment in meta-analyses [31].

A study with a duration of illness of 1 year and 52% of patients experiencing

their first psychotic episode showed that family therapy has limited effectiveness early in the course of the disease [32]. However, the average duration of the disease ranged from 3 to 10 years in studies that demonstrated the effectiveness of family therapy [33]. The lack of family members or the unwillingness of family members to participate in therapy can be a major limitation to family therapy. The PORT project [34] suggests that family therapy can partially mitigate this problem, particularly in older patients.

3.3. Cognitive Behavioral Therapy

CBT attempts to reduce symptoms, reduce the risk of relapse, and facilitate a higher level of functioning through the patient's rational examination of their experiences and reactions to illness [35]. In a conversation with the clinician, the individual can recount his or her story of living with schizophrenia while being assisted in gaining better comprehension to cope with it. At the same time, the clinician can identify any issues that pose particular challenges to the patient [35].

CBT may be practiced in various ways, but all prioritize building a trusting therapeutic relationship and educating patients about schizophrenia and psychosis. It also stresses the importance of taking medicine to control symptoms and keeping relapses at bay. As a result, those undergoing therapy can identify the signs of their condition and relapse, as well as learn stress management techniques, abilities to handle situations, and cognitive restructuring methods to help manage their symptoms [36].

CBT has consistently improved both positive and negative symptoms [37]. According to a meta-analysis focusing exclusively on positive symptoms, CBT patients reduced their positive symptoms by 35% more than controls, and their success rate in reducing positive symptoms increased from 41% to 59% [38]. Using CBT can also improve drug adherence. Compliance therapy (CT), a form of CBT developed specifically to improve medication adherence, has been shown to improve adherence for 18 months after the program ends [37]. Due to its focus on reducing symptoms and relapses, CBT has equivocal effects on global and social functioning. Lack of social and occupational functioning has been associated with a lower perceived quality of life among individuals with schizophrenia [39]. It is also important to consider the timing of CBT. CBT techniques may be more effective during acute psychotic episodes [38].

3.4. Peer Support

An individual with a mental health condition who offers or provides mutual support to another individual with a similar condition is referred to as a peer supporter [40]. Peers of those suffering from schizophrenia can be a valuable source of comfort and understanding. Recent studies have shown that individuals find camaraderie among their peers through peer support programs and improve psychological functioning. This form of community-based help reduces the stigma surrounding mental illness and encourages greater acceptance for all affected by it [40]. It

includes a variety of approaches that enable consumers to share their lived experiences and serve as models, as there is evidence that patients with schizophrenia tend to refuse mental healthcare services [40]. According to the APA guidelines, self-help groups are among the oldest and most widely available interventions, effective in improving symptoms, overall quality of life, even hospitalization rates, treatment adherence, coping strategies, and acceptance of the illness.

3.5. Role of Psychosocial Interventions in Reducing Symptoms and Improving Functioning

Psychosocial interventions provide a comprehensive approach to the management of schizophrenia, targeting symptom reduction and its emotional and social impairments. Studies have shown that individual therapy, family support programs, cognitive behavioral therapies, and peer assistance mechanisms such as supported education initiatives can improve functioning amongst those affected by a higher quality of life [28].

Psychosocial interventions such as individual therapy, family therapy, cognitive behavioral therapy, and peer support can be effective in reducing symptoms of schizophrenia and improving functioning [34]. In addition to addressing the cognitive, emotional, and social impairments associated with the disease, they improve the patient's overall quality of life. These interventions can help patients understand their illness, develop coping strategies, manage their symptoms, and improve their social and interpersonal skills. They can also provide support for caregivers and families. There is evidence that psychosocial interventions can make a significant difference in the lives of people with schizophrenia. These interventions can improve symptoms and functioning and help patients lead fuller, happier lives [41].

3.6. Efficacy of Psychosocial Interventions

The efficacy of psychosocial interventions can vary depending on the phase of schizophrenia (acute versus chronic) and the characteristics of the individual patient. For example, CBT may be more effective during acute psychotic episodes, while family therapy may be more beneficial for patients with a longer duration of the illness. Individual therapy can be customized to address specific symptoms and personal goals, improving patient engagement and motivation. Peer support can be particularly valuable in reducing stigma and improving psychological functioning, especially for those who may be reluctant to engage with traditional mental health services.

3.7. Early Intervention Services (EISs)

Early intervention services (EISs) are critical for improving long-term outcomes in schizophrenia. These services aim to identify and treat people in the early stages of psychosis, often before the full onset of schizophrenia. EIS typically includes pharmacological treatment, psychosocial interventions, and support for education

and employment. The evidence-based benefits of EIS include a reduced duration of untreated psychosis, improved clinical outcomes, and better social and occupational functioning. By providing comprehensive care early on, EIS can help mitigate the long-term impact of schizophrenia and improve the overall quality of life of individuals with the disorder.

4. Coordinated Specialty Care

4.1. Integrated Treatment Approach

The stress-diathesis model supports the need for integrated treatment of schizophrenia. This suggests that symptoms are due to the presence of internal and external elements. Those at risk of developing the disorder likely have a pre-existing biologic susceptibility, believed to be related to genetic influences or issues occurring during gestation, such as prenatal infections or complications during labor. Symptoms result from this vulnerability interacting with environmental aspects such as hardship and substance misuse. As more severe signs typically arise during adolescence, this hints at maturation being an additional factor in the formation [42].

Research on the treatment of schizophrenia has concentrated mainly on either medications or psychosocial techniques. Other assumed treatments, such as the incorporation of medication during a psychosocial treatment, are usually labeled as “conventional treatment” and not carefully monitored. Very few efforts have been conducted regarding unified treatment. Trials that simultaneously monitor a variety of therapies can be hard to carry out but offer the potential for generating data that is not available through other means [42].

May’s early studies were key in establishing the preeminent role of antipsychotic medications in treating positive symptoms. In these examinations, which compared pharmacologic and psychosocial treatment, patients with moderately severe schizophrenia were placed in five groups: milieu therapy, insight-oriented psychotherapy, antipsychotic medication, electroconvulsive therapy, and a combination of antipsychotic medication and individual psychotherapy. The groups that only received medication had better outcomes than others. In particular, those who received combination treatment did not perform better than those who received medication alone [43]. However, according to a study conducted by the National Institute of Mental Health (NIMH) that compared individual supportive psychotherapy with a control condition among chlorpromazine or placebo patients, the results were different. The addition of psychotherapeutic intervention had a positive effect, indicating that approaches could be additive even when medication was still necessary for a positive outcome [44].

Additionally, patients’ social functioning, family attitudes, and family burden were assessed. Over two years, families receiving intensive behavioral intervention demonstrated significantly fewer rejection attitudes toward patients. Family treatment and medication did not affect patients’ social functioning or family burden [45].

These studies of integrated approaches deliver an important message: both medication and psychosocial techniques are effective in differing contexts. Medication alone is beneficial in preventing relapse, while psychosocial treatments can improve quality of life. Moreover, a combination of the two offers a synergistic effect; psychological interventions such as family therapy can reduce relapse beyond any specific dosage level of medications [42].

4.2. Team-Based Care

Team-based care for the management of schizophrenia is a form of treatment that has been proven to be highly effective. The approach involves working with an integrated, multidisciplinary team that generally includes psychiatrists, family physicians, primary care providers, nurses, social workers, therapists, and other mental health professionals [46]. This team provides a comprehensive assessment of the individual's needs and then develops and implements a tailored treatment plan to address those needs. Research has shown that this coordinated and collaborative care can help increase adherence to therapy and improve outcomes for people with schizophrenia. Team care is an important tool for ensuring access to the needed treatment and resources for more effective treatment of the disorder [46].

4.3. Early Identification and Intervention

Early identification and intervention of schizophrenia are critical to decreasing its effects on individuals. Schizophrenia can be very disruptive, resulting in emotional distress and disrupting one's functionality and relationships. Therefore, the signs of early-onset schizophrenia must be quickly identified by medical professionals, such as through assessments for changes in behavior or concerns about future events [47]. Several signs may indicate that someone is developing schizophrenia. These include changes in thinking, mood, and behavior. Early intervention can improve the outcomes for those with the disorder by providing mental health services that enable them to manage their symptoms better and have better long-term functioning over time [47].

4.4. Importance of Continuity of Care

The importance of continuity of care for the treatment of schizophrenia cannot be overstated. This disorder requires comprehensive and comprehensive long-term treatment that involves multiple aspects, from medication to psychotherapy. To ensure an effective approach to managing schizophrenia, a multidisciplinary team with expertise in different areas, such as psychiatry, psychology, occupational therapy, and social work, should work collaboratively over a prolonged period [48]. People with schizophrenia face a variety of difficulties in gaining access to appropriate care, largely due to the fragmented, decentralized, and uncoordinated nature of the mental health system. [49] reported that only one-third of those enrolled in Florida's Medicaid program met the quality standard for visit continuity when

accessing acute treatment and one-fifth during the maintenance phase. Findings from national data on adults with schizophrenia treated by psychiatrists showed that only 8% of Medicare patients and 41% of Medicaid patients received psychotherapy in the past 30 days from a mental health provider [50]. Unfortunately, breaks in care can have serious consequences, such as repeat hospitalizations, homelessness, incarceration, or worst-case suicide [51].

4.5. Role of Evidence-Based Models

Recovery-oriented care and psychological trauma recovery models have been recognized as vital tools for the management of schizophrenia [30]. These evidence-based models are designed to provide comprehensive resources and mechanisms for positive change, including psychosocial interventions, addressing recovery obstacles, and cultivating a meaningful engagement with individuals diagnosed with schizophrenia. At the time of writing, achieving “curation” is probably unrealistic. The term means different things to different people: clinical recovery differs from patient recovery [52]. Despite ongoing symptoms of psychosis, patients describe experiencing personal recovery. As a result, even persistent psychotic symptoms can lead to recovery [53]. As examples of effective utilization of evidence-based practice in behavioral healthcare, these models demonstrate how an integrated team approach can create individualized strategies that allow patients to gain strength, resiliency, and hope. The benefits of these evidence-based practices are vast and include better quality care for people struggling against schizophrenia and improved clinical outcomes [52].

4.6. Cultural Competence and Diversity in the Treatment Approach

Cultural competence and diversity are essential components of effective treatment for schizophrenia. Recognizing and respecting patients’ cultural backgrounds, beliefs, and values can significantly improve the therapeutic relationship and treatment results.

4.6.1. Understanding Cultural Differences

Here are key considerations for incorporating cultural competence and diversity into the treatment approach.

1) Cultural beliefs and stigma: Different cultures have varying beliefs about mental illness, which can influence how patients perceive their condition and treatment. Some cultures may have strong stigmas associated with mental illness, leading to a reluctance to seek help. Understanding these beliefs can help healthcare professionals address concerns and reduce stigma.

2) Communication styles: Effective communication is crucial to building trust and understanding. Healthcare providers should be aware of cultural differences in communication styles, including language preferences, nonverbal cues, and levels of formality. Using interpreters or culturally appropriate materials can facilitate better communication.

3) Family dynamics: In many cultures, the family plays a central role in decision-making and caregiving. The participation of family members in the treatment process can provide additional support and improve adherence to treatment plans. Understanding family dynamics and respecting their role can enhance the effectiveness of interventions.

4.6.2. Tailoring Treatment Plans

1) Culturally adapted interventions: Adapting therapeutic interventions to align with cultural values and practices can improve engagement and outcomes. For example, incorporating culturally relevant examples and metaphors in cognitive behavioral therapy (CBT) can make therapy more relatable and effective.

2) Holistic approaches: Some cultures emphasize holistic approaches to health, which integrate physical, mental, and spiritual well-being. Incorporating holistic practices, such as mindfulness, meditation, or traditional healing methods, can complement conventional treatments and resonate with cultural beliefs.

3) Addressing social determinants of health: Cultural competence also involves understanding the social determinants of health that affect diverse populations. Socioeconomic status, access to healthcare care, education, and housing can affect treatment adherence and outcomes. Addressing these determinants through community resources and support services is crucial.

4.6.3. Training and Education

1) Cultural competence training: Healthcare providers should receive cultural competence to enhance their understanding and skills in working with diverse populations. This training can include cultural awareness, implicit bias, and effective communication strategies.

2) Ongoing education: Staying informed about the cultural backgrounds and needs of the patient population is essential. Ongoing education and self-reflection can help providers remain culturally sensitive and responsive to changing demographics.

3) Collaboration with cultural experts: Collaborating with cultural experts, community leaders, and organizations can provide valuable information and resources for providing culturally competent care. These partnerships can help bridge cultural gaps and improve access to services.

5. Challenges and Future Directions

5.1. Improving Approaches to Medication Development

The management of schizophrenia presents an array of unmet needs that require attention in the future. Although there are many treatment options available for schizophrenia, many people still experience severe symptoms and adverse effects from medication use, resulting in poor adherence or worse outcomes as a result of insufficient access to services. It has been more than sixty years since the discovery of clozapine, yet there have been no groundbreaking improvements in

psychopharmacology for schizophrenia. This is even more concerning because of the recent move of the pharmaceutical industry away from research and development in psychiatric disorders. The benefits of antipsychotics and the advantages of SGA are still not enough, as the medications lack effectiveness and often come with harsh side effects [9].

It is becoming increasingly clear that schizophrenia is not a single disease entity, and antipsychotics are effective at treating only one aspect of its pathology, namely the positive symptoms of psychosis like delusions and hallucinations. In the future, pharmaceutical development should focus on the symptom domains of schizophrenia, with a special focus on treatments that address negative symptoms and cognitive impairments. A sharper focus on the different symptom areas may result in endophenotypic markers being identified for negative symptoms, cognitive deficits, and positive symptoms. This could promote the development of new drugs. If these medications target each domain of symptoms of schizophrenia, concurrent medication strategies could be used, such as antipsychotics combined with agents that address negative signs or those that have a cognitive-enhancing effect [9].

Schizophrenia's current treatment is D2-receptor blockers, although some treatments have been tested on nondopaminergic mechanisms. While some evidence suggests that modulating the function of the N-methyl-D-aspartate receptor or nicotinic receptor signaling could help with negative and cognitive symptoms, replicated evidence of its effectiveness is lacking. Scientists continue to gain knowledge about schizophrenia pathogenesis, hoping that novel therapies can be developed in the future that will rationally target cellular and molecular targets rather than just D2 receptors [9].

5.2. Neuroscience and Genetic Development

Neuroscience and genetics research on schizophrenia has uncovered many issues that must be addressed to foster successful treatment. Despite considerable research into the cause and pathology of schizophrenia since the last century, a definitive answer remains absent. Various suggested hypotheses include GABAergic dysfunction, which is often reported in cases of schizophrenia, yet a satisfactory mechanism for therapeutic purposes has not yet been developed [54]. Also, there is a molecular neuropathology shared by schizophrenia and bipolar disorder, and bipolar has synaptic dysfunction similar to schizophrenia, increasing the possibility of misclassifying patients. As a potential marker for different disorders, neuronal firing rate differences should be examined to determine whether firing rate differences exist between psychiatric diseases [54].

5.3. Incorporating AI and Machine Learning Approaches

There are several strengths to MRI-based radionics/machine learning studies in schizophrenia, including biological foundations (structure/function), an extension of treatment prediction (AP/ECT), and validation methods (inter-/intra-data

set CV). From a clinical and research perspective, this field faces many critical challenges [55]. Clinical diagnosis is the gold standard in most classification studies; however, with MRIs or psychopathology, some recent studies have explored transdiagnostic characteristics of mental disorders to break down the boundaries of classic diagnosis and establish bioinformation-based disorder classifications. Furthermore, several novel machine learning models have been applied to large multicenter MRI data, such as generative adversarial networks (GANs), and improved the reproducibility of radiomic features between manufacturers. GANs also improve diagnostic accuracy. It is considered an initiative and an important development in precision medicine for mental disorders to use “radiomics” combining novel machine learning models [55]. Personalizing medicine using neuroimaging can uncover biological mechanisms connected with the condition, proving it to set a strong foundation from which new treatments can be developed [56]. Ultimately, these developments will help provide more effective interventions tailored to individuals.

5.4. Improving Access to Care and Reducing Disparities

By making strides to bridge the disparities currently facing those with schizophrenia, we hope to create more equitable access to care ultimately. Insurance coverage issues, the stigma surrounding the disorder, and limited resources can severely impede a person’s quality of life and ability to mitigate symptoms. Therefore, steps must be taken to create an environment where everyone has the opportunity to strive for optimal health outcomes. To drive equitable access to mental health care, groundbreaking strategies like telepsychiatry and virtual reality are proving effective for those in remote or underserved communities [57]. Integrating culturally responsive practices with evidence-based methods makes it possible to close the gap between minority ethnicities facing disparities in quality of care [58]. By tailoring treatment plans to the specific biological, genetic, and environmental characteristics of an individual, we may be able to improve care outcomes for those suffering from schizophrenia and reduce the unequal access that currently exists [59].

6. Conclusion

The 21st century has seen significant improvements in the management of schizophrenia, but challenges remain. To maximize positive outcomes, a comprehensive and integrated approach is needed that incorporates medications, psychosocial interventions, and specialized care. Increasing the accuracy of diagnosis, classification, and therapy in the future can be improved through early detection and prevention, as well as the utilization of new antipsychotic drugs, drugs that address negative symptoms, treatment modalities such as rTMS, and sophisticated mathematical analysis. Moreover, it is essential to address the varied needs of patients and their families through personalized diagnostic and treatment plans. Furthermore, using available technologies and treatments while simultaneously eliminating

disparities in access to care has immense potential for optimizing patient outcomes and improving quality of life. Research into neuroscience, genetics, and implementation science could lead to a better understanding of schizophrenia with more effective management strategies implemented accordingly.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- [1] Elvevag, B. and Goldberg, T.E. (2000) Cognitive Impairment in Schizophrenia Is the Core of the Disorder. *Critical Reviews in Neurobiology*, **14**, 1-21. <https://doi.org/10.1615/critrevneurobiol.v14.i1.10>
- [2] Bradshaw, T., Lovell, K., Bee, P. and Mairs, H. (2005) Why Do Adults with Schizophrenia Have Poorer Physical Health than the Rest of the Population? *Mental Health Practice*, **9**, 28-30. <https://doi.org/10.7748/mhp2005.12.9.4.28.c1897>
- [3] Read, J.H. (2013) Prejudice, Stigma and “Schizophrenia”: The Role of Bio-Genetic Ideology. In: *Models of Madness: Psychological, Social and Biological Approaches to Psychosis*, Routledge, 157-177.
- [4] Janoutová, J.J. (2016) Epidemiology and Risk Factors of Schizophrenia. *Neuroendocrinology Letters*, **37**, 1-8.
- [5] Medalia, A. and Choi, J. (2009) Cognitive Remediation in Schizophrenia. *Neuropsychology Review*, **19**, 353-364. <https://doi.org/10.1007/s11065-009-9097-y>
- [6] Such, P., Olivares, J.M., Arias, L., Troels Berg, M. and Madera, J. (2021) Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate. *Neuropsychiatric Disease and Treatment*, **17**, 1881-1892. <https://doi.org/10.2147/ndt.s303292>
- [7] Kasckow, J., Felmet, K., Appelt, C., Thompson, R., Rotondi, A. and Haas, G. (2014) Telepsychiatry in the Assessment and Treatment of Schizophrenia. *Clinical Schizophrenia & Related Psychoses*, **8**, 21-27. <https://doi.org/10.3371/csrfp.kafe.021513>
- [8] Montoya, N., Hawkins, B., Townsend, J. and Lewis, S. (2020) Use of Evidence-Based Practices in Recreational Therapy for Schizophrenia Spectrum Disorder Recovery: A Descriptive Study of Current Practices. *Therapeutic Recreation Journal*, **54**, 128-149. <https://doi.org/10.18666/trj-2020-v54-i2-9962>
- [9] Lally, J. and MacCabe, J.H. (2015) Antipsychotic Medication in Schizophrenia: A Review. *British Medical Bulletin*, **114**, 169-179. <https://doi.org/10.1093/bmb/ldv017>
- [10] Stroup, T.S. and Gray, N. (2018) Management of Common Adverse Effects of Antipsychotic Medications. *World Psychiatry*, **17**, 341-356. <https://doi.org/10.1002/wps.20567>
- [11] Klein, M.O., Battagello, D.S., Cardoso, A.R., Hauser, D.N., Bittencourt, J.C. and Correa, R.G. (2018) Dopamine: Functions, Signaling, and Association with Neurological Diseases. *Cellular and Molecular Neurobiology*, **39**, 31-59. <https://doi.org/10.1007/s10571-018-0632-3>
- [12] Sikich, L., Frazier, J.A., McClellan, J., Findling, R.L., Vitiello, B., Ritz, L., et al. (2008) Double-blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-Affective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. *American Journal of Psychiatry*, **165**, 1420-1431. <https://doi.org/10.1176/appi.ajp.2008.08050756>

- [13] Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., *et al.* (2013) Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. *The Lancet*, **382**, 951-962. [https://doi.org/10.1016/s0140-6736\(13\)60733-3](https://doi.org/10.1016/s0140-6736(13)60733-3)
- [14] Mitchell, A.J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W. and de Hert, M. (2011) Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis. *Schizophrenia Bulletin*, **39**, 306-318. <https://doi.org/10.1093/schbul/sbr148>
- [15] Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., *et al.* (1999) Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. *American Journal of Psychiatry*, **156**, 1686-1696. <https://doi.org/10.1176/ajp.156.11.1686>
- [16] Samara, M.T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., *et al.* (2016) Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia. *JAMA Psychiatry*, **73**, 199-210. <https://doi.org/10.1001/jamapsychiatry.2015.2955>
- [17] Porcelli, S., Balzarro, B. and Serretti, A. (2012) Clozapine Resistance: Augmentation Strategies. *European Neuropsychopharmacology*, **22**, 165-182. <https://doi.org/10.1016/j.euroneuro.2011.08.005>
- [18] Kontaxakis, V.P., Ferentinos, P.P., Havaki-Kontaxaki, B.J., Paplos, K.G., Pappa, D.A. and Christodoulou, G.N. (2006) Risperidone Augmentation of Clozapine. *European Archives of Psychiatry and Clinical Neuroscience*, **256**, 350-355. <https://doi.org/10.1007/s00406-006-0643-9>
- [19] Nucifora, F.C., Woznica, E., Lee, B.J., Cascella, N. and Sawa, A. (2019) Treatment Resistant Schizophrenia: Clinical, Biological, and Therapeutic Perspectives. *Neurobiology of Disease*, **131**, Article ID: 104257. <https://doi.org/10.1016/j.nbd.2018.08.016>
- [20] Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X. and Korhonen, P. (2011) A Nationwide Cohort Study of Oral and Depot Antipsychotics after First Hospitalization for Schizophrenia. *American Journal of Psychiatry*, **168**, 603-609. <https://doi.org/10.1176/appi.ajp.2011.10081224>
- [21] Keks, N.A., Ingham, M., Khan, A. and Karcher, K. (2007) Long-Acting Injectable Risperidone Olanzapine Tablets for Schizophrenia or Schizoaffective Disorder. *British Journal of Psychiatry*, **191**, 131-139. <https://doi.org/10.1192/bjp.bp.105.017020>
- [22] Kim, H.O., Seo, G.H. and Lee, B.C. (2020) Real-World Effectiveness of Long-Acting Injections for Reducing Recurrent Hospitalizations in Patients with Schizophrenia. *Annals of General Psychiatry*, **19**, Article No. 1. <https://doi.org/10.1186/s12991-019-0254-2>
- [23] Brissos, S., Veguilla, M.R., Taylor, D. and Balanzá-Martinez, V. (2014) The Role of Long-Acting Injectable Antipsychotics in Schizophrenia: A Critical Appraisal. *Therapeutic Advances in Psychopharmacology*, **4**, 198-219. <https://doi.org/10.1177/2045125314540297>
- [24] Chaudhari, B., Saldanha, D., Kadiani, A. and Shahani, R. (2017) Evaluation of Treatment Adherence in Outpatients with Schizophrenia. *Industrial Psychiatry Journal*, **26**, 215-222. https://doi.org/10.4103/ipj.ipj_24_17
- [25] Edelman, E.M. (2010) Patients' Perception of Family Involvement and Its Relationship to Medication Adherence for Persons with Schizophrenia and Schizoaffective Disorders. <https://rucore.libraries.rutgers.edu/rutgers-lib/27445/>
- [26] Haddad, C., Salameh, P., Sacre, H., Clément, J. and Calvet, B. (2023) Effects of Antipsychotic and Anticholinergic Medications on Cognition in Chronic Patients with

- Schizophrenia. *BMC Psychiatry*, **23**, Article No. 61. <https://doi.org/10.1186/s12888-023-04552-y>
- [27] Solmi, M., Croatto, G., Piva, G., Rosson, S., Fusar-Poli, P., Rubio, J.M., *et al.* (2022) Efficacy and Acceptability of Psychosocial Interventions in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-Analytic Evidence. *Molecular Psychiatry*, **28**, 354-368. <https://doi.org/10.1038/s41380-022-01727-z>
- [28] Ventriglio, A., Ricci, F., Magnifico, G., Chumakov, E., Torales, J., Watson, C., *et al.* (2020) Psychosocial Interventions in Schizophrenia: Focus on Guidelines. *International Journal of Social Psychiatry*, **66**, 735-747. <https://doi.org/10.1177/0020764020934827>
- [29] Agrawal, A., Kaur, R.D. and Sidana, A. (2022) Cognitive Behavioral Therapy-Based Approach for Management of Persistent Hallucinations in Treatment-Resistant Schizophrenia. *Industrial Psychiatry Journal*, **31**, 376-377. https://doi.org/10.4103/ipj.ipj_137_21
- [30] Mueser, K.T., Deavers, F., Penn, D.L. and Cassisi, J.E. (2013) Psychosocial Treatments for Schizophrenia. *Annual Review of Clinical Psychology*, **9**, 465-497. <https://doi.org/10.1146/annurev-clinpsy-050212-185620>
- [31] Pilling, S., Bebbington, P., Kuipers, E., Garety, P., Geddes, J., Orbach, G., *et al.* (2002) Psychological Treatments in Schizophrenia: I. Meta-Analysis of Family Intervention and Cognitive Behaviour Therapy. *Psychological Medicine*, **32**, 763-782. <https://doi.org/10.1017/s0033291702005895>
- [32] Lenior, M.E., Dingemans, P.M.A.J., Linszen, D.H., De Haan, L. and Schene, A.H. (2001) Social Functioning and the Course of Early-Onset Schizophrenia. *British Journal of Psychiatry*, **179**, 53-58. <https://doi.org/10.1192/bjp.179.1.53>
- [33] Li, Z. and Arthur, D. (2005) Family Education for People with Schizophrenia in Beijing, China. *British Journal of Psychiatry*, **187**, 339-345. <https://doi.org/10.1192/bjp.187.4.339>
- [34] Lehman, A.F. and Steinwachs, D.M. (2003) Evidence-Based Psychosocial Treatment Practices in Schizophrenia: Lessons from the Patient Outcomes Research Team (PORT) Project. *The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry*, **31**, 141-154. <https://doi.org/10.1521/jaap.31.1.141.21939>
- [35] Dickerson, F.B. and Lehman, A.F. (2006) Evidence-Based Psychotherapy for Schizophrenia. *Journal of Nervous & Mental Disease*, **194**, 3-9. <https://doi.org/10.1097/01.nmd.0000195316.86036.8a>
- [36] Bellack, A.S. (2004) Skills Training for People with Severe Mental Illness. *Psychiatric Rehabilitation Journal*, **27**, 375-391. <https://doi.org/10.2975/27.2004.375.391>
- [37] Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. and David, A. (1996) Compliance Therapy in Psychotic Patients: Randomised Controlled Trial. *British Medical Journal*, **312**, 345-349. <https://doi.org/10.1136/bmj.312.7027.345>
- [38] Zimmermann, G., Favrod, J., Trieu, V.H. and Pomini, V. (2005) The Effect of Cognitive Behavioral Treatment on the Positive Symptoms of Schizophrenia Spectrum Disorders: A Meta-Analysis. *Schizophrenia Research*, **77**, 1-9. <https://doi.org/10.1016/j.schres.2005.02.018>
- [39] Bengtsson-Tops, A. and Hansson, L. (1999) Subjective Quality of Life in Schizophrenic Patients Living in the Community. Relationship to Clinical and Social Characteristics. *European Psychiatry*, **14**, 256-263. [https://doi.org/10.1016/s0924-9338\(99\)00173-x](https://doi.org/10.1016/s0924-9338(99)00173-x)
- [40] Repper, J. and Watson, E. (2012) A Year of Peer Support in Nottingham: Lessons Learned.

The Journal of Mental Health Training, Education and Practice, 7, 70-78.

<https://doi.org/10.1108/17556221211236466>

- [41] Holmedal Byrne, K. and Gustafsson, B.M. (2024) Implementation Study of “Building Resilience,” Including Positive Psychology Interventions and Positive Emotion Regulation Training in Patients with Severe Mental Illness in an Adult Outpatient Psychiatric Mental Health Setting: An Exploratory Clinical Trial. *Behavior Modification*, 48, 537-560. <https://doi.org/10.1177/01454455241269842>
- [42] Lenroot, R., Bustillo, J.R., Lauriello, J. and Keith, S.J. (2003) Integration of Care: Integrated Treatment of Schizophrenia. *Psychiatric Services*, 54, 1499-1507. <https://doi.org/10.1176/appi.ps.54.11.1499>
- [43] May, P.R. (1968) Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. Science House.
- [44] Hogarty, G.E. (1974) Drug and Sociotherapy in the Aftercare of Schizophrenic Patients. *Archives of General Psychiatry*, 31, 609-618. <https://doi.org/10.1001/archpsyc.1974.01760170011002>
- [45] Mueser, K.T., Sengupta, A., Schooler, N.R., Bellack, A.S., Xie, H., Glick, I.D., et al. (2001) Family Treatment and Medication Dosage Reduction in Schizophrenia: Effects on Patient Social Functioning, Family Attitudes, and Burden. *Journal of Consulting and Clinical Psychology*, 69, 3-12. <https://doi.org/10.1037/0022-006x.69.1.3>
- [46] Falloon, I.R.H., Held, T., Roncone, R., Coverdale, J.H. and Laidlaw, T.M. (1998) Optimal Treatment Strategies to Enhance Recovery from Schizophrenia. *Australian & New Zealand Journal of Psychiatry*, 32, 43-49. <https://doi.org/10.3109/00048679809062704>
- [47] Lin, C. and Lane, H. (2019) Early Identification and Intervention of Schizophrenia: Insight from Hypotheses of Glutamate Dysfunction and Oxidative Stress. *Frontiers in Psychiatry*, 10, Article 93. <https://doi.org/10.3389/fpsy.2019.00093>
- [48] American Psychiatric Association (2006) American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006.
- [49] Busch, A.B., Lehman, A.F., Goldman, H. and Frank, R.G. (2009) Changes over Time and Disparities in Schizophrenia Treatment Quality. *Medical Care*, 47, 199-207. <https://doi.org/10.1097/mlr.0b013e31818475b7>
- [50] West, J.C., Wilk, J.E., Olfson, M., Rae, D.S., Marcus, S., Narrow, W.E., et al. (2005) Patterns and Quality of Treatment for Patients with Schizophrenia in Routine Psychiatric Practice. *Psychiatric Services*, 56, 283-291. <https://doi.org/10.1176/appi.ps.56.3.283>
- [51] Kreyenbuhl, J., Nossel, I.R. and Dixon, L.B. (2009) Disengagement from Mental Health Treatment among Individuals with Schizophrenia and Strategies for Facilitating Connections to Care: A Review of the Literature. *Schizophrenia Bulletin*, 35, 696-703. <https://doi.org/10.1093/schbul/sbp046>
- [52] Emsley, R., Chiliza, B., Asmal, L. and Lehloeny, K. (2011) The Concepts of Remission and Recovery in Schizophrenia. *Current Opinion in Psychiatry*, 24, 114-121. <https://doi.org/10.1097/ycp.0b013e3283436ea3>
- [53] Bellack, A.S. (2005) Scientific and Consumer Models of Recovery in Schizophrenia: Concordance, Contrasts, and Implications. *Schizophrenia Bulletin*, 32, 432-442. <https://doi.org/10.1093/schbul/sbj044>
- [54] Jahangir, M., Zhou, J., Lang, B. and Wang, X. (2021) Gabaergic System Dysfunction and Challenges in Schizophrenia Research. *Frontiers in Cell and Developmental Biology*, 9, Article 663854. <https://doi.org/10.3389/fcell.2021.663854>

- [55] Cui, L., Xu, X. and Cao, F. (2021) Building the Precision Medicine for Mental Disorders via Radiomics/Machine Learning and Neuroimaging. *Frontiers in Neuroscience*, **15**, Article 685005. <https://doi.org/10.3389/fnins.2021.685005>
- [56] Vita, A., Minelli, A., Barlati, S., Deste, G., Giacomuzzi, E., Valsecchi, P., *et al.* (2019) Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. *Frontiers in Pharmacology*, **10**, Article 402. <https://doi.org/10.3389/fphar.2019.00402>
- [57] Maheu, M.M., Pulier, M.L., McMenamin, J.P. and Posen, L. (2012) Future of Telepsychology, Telehealth, and Various Technologies in Psychological Research and Practice. *Professional Psychology: Research and Practice*, **43**, 613-621. <https://doi.org/10.1037/a0029458>
- [58] Alegría, M., Alvarez, K., Ishikawa, R.Z., DiMarzio, K. and McPeck, S. (2016) Removing Obstacles to Eliminating Racial and Ethnic Disparities in Behavioral Health Care. *Health Affairs*, **35**, 991-999. <https://doi.org/10.1377/hlthaff.2016.0029>
- [59] Satcher, D. (2000) Mental Health: A Report of the Surgeon General—Executive Summary. *Professional Psychology: Research and Practice*, **31**, 5-13. <https://doi.org/10.1037/0735-7028.31.1.5>